Abstract
PurposeTo develop a mapping algorithm for generating EQ-5D-5-level (EQ-5D-5L) utility scores from the Dermatology Life Quality Index (DLQI) in patients with atopic dermatitis (AD).MethodsThe algorithm was developed using data from 1232 patients from four countries participating in the National Health and Wellness Study. Spearman’s rank correlation coefficient was used to evaluate the conceptual overlap between DLQI and EQ-5D-5L. Six mapping models (ordinary least squares [OLS], Tobit, three different two-part models, and a regression mixture model) were tested with different specifications to determine model performance and were ranked based on the sum of mean absolute error (MAE), and root mean squared error (RMSE).ResultsThe mean DLQI score was 7.23; mean EQ-5D-5L score was 0.78; and there were moderate negative correlations between DLQI and EQ-5D-5L scores (p = − 0.514). A regression mixture model with total DLQI, and age and sex as independent variables performed best for mapping DLQI to EQ-5D-5L (RMSE = 0.113; MAE = 0.079).ConclusionThis was the first study to map DLQI to EQ-5D-5L exclusively in patients with AD. The regression mixture model with total DLQI, and age and sex as independent variables was the best performing model and accurately predicted EQ-5D-5L. The results of this mapping can be used to translate DLQI data from clinical studies to health state utility values in economic evaluations.
Highlights
Atopic dermatitis (AD) is a chronic, inflammatory skin condition with a wide range of symptoms affecting the skin, and the immune system, sleep, mental health, and quality of life (QoL) [1]
This paper reports the results of a direct mapping study that developed algorithms to map non-preference-based Dermatology Life Quality Index (DLQI) scores to preference-based EQ5D-5L utility scores in patients with AD
There was a weaker correlation between DLQI items and EQ-5D utility scores compared to EQ-5D dimensions and total DLQI score
Summary
Atopic dermatitis (AD) is a chronic, inflammatory skin condition with a wide range of symptoms affecting the skin, and the immune system, sleep, mental health, and quality of life (QoL) [1]. QoL is measured in less than 30% of AD studies [3], and there is no single instrument recommended to measure health-related QoL (HRQL) in patients with AD [4], with some reviews finding up to 18 different measures used in AD studies [3]. According to a systematic review, only 63 of 303 studies in AD assessed QoL with 21 studies using the Dermatology Life Quality Index (DLQI), while only one study used the EQ-5D [7].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.